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ualberta.ca (S. Sipione).Simple sphingolipids such as ceramide and sphingomyelin (SM) as well as more complex glyco-
sphingolipids play very important roles in cell function under physiological conditions and during
disease development and progression. Sphingolipids are particularly abundant in the nervous sys-
tem. Due to their amphiphilic nature they localize to cellular membranes and many of their roles
in health and disease result frommembrane reorganization and from lipid interaction with proteins
within cellular membranes. In this review we discuss some of the functions of sphingolipids in pro-
cesses that entail cellular membranes and their role in neurodegenerative diseases, with an empha-
sis on SM, ceramide and gangliosides.
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pids (Fig. 1) and is at the hub of sphingolipid metabolism (Fig. 2).
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Posse de Chaves), ssipione@Gangliosides are GSLs that contain sialic acid [1,2].
The nervous system of mammals is rich in SM [3] and GSLs [2].
Gangliosides are major components of neuronal membranes,
where they contribute up to 10–12% of the total lipid content
and participate in crucial processes of the nervous system [2]. Their
regulatory roles are suggested by the dramatic change in the pat-
tern of gangliosides expressed during development of the nervous
system, as well as by the region-speciﬁc distribution of ganglio-
sides with different carbon chain length in the ceramide moiety
[4]. The brain content of SM, ceramide and GSLs changes through-
out life, during aging and in neurodegenerative diseases; some of
these changes are discussed below.
2. Sphingolipids: master regulators of membrane dynamics
Sphingolipids have a natural predisposition to lateral segrega-
tion within membranes and to the formation of membrane micro-
domains (or lipid rafts) that are also enriched with cholesterol. The
unique conformation of the amide group and the hydroxyl group
on C3 of the ceramide moiety allows for the establishment of a net-
work of hydrogen bonds at the water/lipid interface that stabilizes
sphingolipid-enriched microdomains. Lateral segregation of
gangliosides and other GSLs is further favored by the formationlsevier B.V. All rights reserved.
Fig. 1. Structure of sphingolipids and ganglioside biosynthesis pathway. Sphingolipids derive from long-chain amino alcohols (sphingoid bases). Complex sphingolipids and
gangliosides share a ceramide backbone formed by the sphingoid base (mainly sphingosine) linked to a long-chain fatty acid (C:16, C:18 or longer). The primary alcoholic
group of ceramide is attached to phosphocholine or saccharides, producing sphingomyelin, and glycosphingolipids, respectively. One or more saccharides may be linked to
ceramide. Gangliosides are mono- or multi-sialosylated glycosphingolipids. Their synthesis is a multi-step process in which a sugar is ﬁrst added to ceramide, followed by
stepwise addition of other saccharide residues to the growing glycan. The major gangliosides in the brain are GM1, GD1a, GD1b and GT1b.
Fig. 2. Compartmentalization of sphingolipid and ganglioside metabolism. Ceramide synthesized in the endoplasmic reticulum is transported to the Golgi apparatus where it
is converted to SM and GSLs. From the Golgi, SM and GSLs are transported by vesicular transport to lipid raft domains at the plasma membrane. SM is converted to ceramide
by acid or neutral SMases. Ceramide segregates laterally forming big ceramide platforms poor in cholesterol. GM3 is also converted to ceramide by the action of sialidases and
glycohydrolases. Also represented is the interaction of transmembrane proteins with gangliosides in the formation of lipid shells that favors the recruitment of proteins to
lipid rafts. SM and GSLs catabolism at the lysosomes provides ceramide and sphingosine to the ‘salvage’ pathway. In particular circumstances, ceramide can also be derived
from sphingomyelin in the mitochondria.
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play very important roles in a variety of cellular processes includ-
ing membrane trafﬁcking, signal transduction, cytoskeletal organi-
zation, etc. The biophysical and physiological aspects of lipid rafts
are discussed elsewhere in this special issue.
Proteins that associate with lipid rafts tend to have glycosyl
phosphatidylinositol (GPI) anchors, or to be dually acylated, palm-
itoylated, or associated to cholesterol. Transmembrane proteins
may have cholesterol and sphingolipid-containing ‘‘lipid shells”
that stably interact with speciﬁc aminoacid residues in the trans-
membrane domains of the protein, and that favor protein segrega-
tion into lipid rafts (Fig. 2). These protein-speciﬁc lipid shells, are
stabilized by the speciﬁc interaction of the sugar headgroup of
the ganglioside with the protein oligosaccharide chains or amino-
acids [5]. Because ‘raft’ proteins tend to have reduced lateral
mobility, protein–protein interactions are facilitated within partic-
ular lipid microdomains.
The roles of sphingolipids in biological membranes, however,
extend well beyond the formation of lipid rafts. In fact, sphingoli-
pids are highly dynamic lipids that modulate membrane composi-
tion and behavior through their reciprocal interconversion and the
formation of speciﬁc lipid–protein interactions. For instance, local
conversion of SM to ceramide, by the action of one of several SMas-
es1 at the plasma membrane, is a regulated event that has profound
effects on the biophysical properties of the membrane and on cell
function. Many cellular functions of ceramide have been explained
based on these changes [6]. Since ceramide mixes more poorly than
SM with glycerophospholipids and cholesterol [6,7], SM conversion
to ceramide results in the formation of large ceramide-enriched do-
mains (ceramide platforms) that exclude cholesterol and alter the
composition of lipid rafts (Fig. 2) [7–10].
Ceramide-induced lateral lipid separation has also profound ef-
fects on membrane proteins. Different proteins are recruited or ex-
cluded from ceramide platforms depending on their relative
afﬁnity for cholesterol and ceramide. One consequence of this dif-
ferential afﬁnity is the clustering of plasma membrane receptors
upon ceramide generation, a phenomenon studied in detail for
receptors such as Fas and CD40 [6]. A second consequence of the
changes in membrane microdomains that results from SM conver-
sion to ceramide is the speciﬁc recruitment of ancillary proteins to
receptor complexes. That is the case for the recruitment of caveo-
lin-1 to phosphoinositide 3-kinase (PI3K)-associated receptor com-
plexes within lipid raft, which causes inactivation of PI3K [11].
Ceramide generated from SM at the plasma membrane also in-
duces pore formation and increases membrane permeability
through transmembrane ceramide channels, causing abnormal ﬂux
of calcium and other ions that affects the activity of local enzymes
[6,12]. In addition, the change of membrane curvature that takes
place upon ceramide accumulation could also alter the three-
dimensional structure of membrane enzymes causing their activa-
tion or inhibition [6]. Finally, lateral lipid separation and ceramide-
rich domain formation create membrane-packing defects that
might allow and/or facilitate the interaction of ceramide with its
direct target proteins.
Contrary to the well-deﬁned regulatory roles of the SM cycle,
the conversion of gangliosides to ceramide at the plasma mem-
brane has only started to be appreciated lately. Ceramide can be
generated at the plasma membrane from ganglioside GM3 by the
combined action of the sialidase N-acetyl-a-neuraminidase 3
(Neu3), which is highly expressed in the brain, and membrane-
bound glycosylhydrolases [13]. In principle, ganglioside-derived
ceramide would trigger the same changes in membrane dynamics1 For the purpose of this review we will not differentiate in detail the different
SMases.that are induced by SM-derived ceramide, although the size of the
ceramide pool generated from gangliosides could be smaller. How-
ever, the cellular outcome would be very different due to the con-
comitant decrease of ganglioside levels and the consequent loss of
speciﬁc lipid–protein interactions. The sialidase Neu3 is also
responsible for the modulation of plasma membrane ganglioside
composition in a focal and regulated manner. As discussed later,
these changes may profoundly affect cell signaling.
3. Modulation of membrane protein activity and signaling
Sphingolipids and gangliosides are important modulators of
membrane receptors, ion channels and downstream signaling
pathways. Regulation occurs by different mechanisms, some of
which are rather general and others that are receptor and/or gan-
glioside-speciﬁc. The list of membrane proteins regulated by
sphingolipids and gangliosides will likely grow as we increase
our understanding of membrane dynamics and protein–lipid
interactions.
3.1. Regulation through changes in the membrane composition
A general mechanism of regulation of receptors and ion chan-
nels by sphingolipids and gangliosides involves their recruitment
or exclusion, along with associated proteins, to speciﬁc GSL- or cer-
amide-enriched membrane microdomains. The composition of
these domains affects protein–protein interactions and/or receptor
trafﬁcking. This is probably the case for the platelet-derived
growth factor (PDGF) receptor, the activation of which is inhibited
by most complex gangliosides. Experimental overexpression of
GM1 blocks PDGF receptor signaling by displacing it outside of li-
pid rafts [14], suggesting that local accumulation of GM1 might
modulate receptor function. In physiological conditions, focal in-
crease of GM1 might result from regulated activation of Neu3 by
the transmembrane adaptor protein phosphoprotein associated
with glycospingolipid-enriched microdomains (PAG-N) in caveo-
lin-associated microdomains [15]. Thus, although the mechanism
is somehow general (movement of the receptor outside of lipid
rafts) the trigger of ganglioside accumulation is speciﬁc.
A common mechanism of membrane protein regulation by cer-
amide involves the formation of ceramide-rich platforms upon
activation of SMases. An example is the activation of tropomyo-
sin-receptor kinase A (TrkA) by ceramide in the absence of the TrkA
ligand nerve growth factor (NGF) (reviewed in [16]). This activa-
tion takes place within low-buoyancy membranes, enriched in cer-
amide and with low cholesterol content.2 In this particular case the
recruitment of TrkA to ceramide-rich domains would be sufﬁcient
for receptor activation based on the evidence that TrkA dimerizes
and autoactivates in the absence of NGF when its concentration at
the plasma membrane reaches a high enough level [17].
Themechanism ofmembrane protein regulation by formation of
ceramide-rich platformshas been studied in detail in the case of cer-
amide-induced Kv1.3 inhibition. Kv1.3 belongs to the group of sha-
ker channels, which in the central nervous system are found
primarily in axons where they modulate electrical activity. Kv1.3
channels require raft localization for proper function. The formation
of ceramide-rich platforms inhibits Kv1.3 activity directly by chang-
ing the lipid composition of rafts, and possibly indirectly by bringing
together the channel with Src-like tyrosine kinases (SFK), which
cause phosphorylation of Kv1.3 [18]. Several other ion channels
are regulated by ceramide in a similar lipid raft/SFK dependent fash-
ion [19]. The ‘‘recruitment” effect to ceramide platforms is not spe-
ciﬁc to SFK, and could also explain the activation of other signaling2 Posse de Chaves et al., unpublished observations.
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channels, such as c-Jun-N-terminal kinase (JNK) [20] and protein ki-
nase C (PKC) [21]. For example, the rapid and focal generation of cer-
amide downstream of the inﬂammatory cytokine TNFa determines
activation of the N-methyl-D-aspartate (NMDA) receptor and excit-
atory post-synaptic currents by recruiting in close proximity and
clustering into ceramide-rich platforms both the NMDA receptor
subunitNR1 [22] and thekinases thatphosphorylate it, PKCandPKA.
The inﬂammatory cytokine interleukin (IL) 1b regulates ion
channels activity in a similar manner. Binding of interleukin 1b
(IL1b) to its receptor IL1R1 activates SMases and ceramide produc-
tion [23]. Ceramide mediates the fast, non-transcription-depen-
dent effects of IL-1b [24,25], which have been linked to the
development of epilepsy [26], seizures [27] and rapid induction
of fever [24]. Recruitment of Src kinases to the IL-1 signaling com-
plex leads to ion channels phosphorylation pre- or post-synaptical-
ly [25]. In particular, tyrosine phosphorylation of NMDA receptor
NR2B subunit mediated by ceramide-activated SFK is responsible
for the pro-convulsive effects of IL-1b [27].
Like ceramide, GSLs modulate the activity of SFKs through
recruitment into lipid rafts. Gangliosides (GD1b in particular) are
closely associated to c-Src and Lyn in lipid rafts [28]. The outcome
of the association of these signaling molecules with GSL-enriched
microdomains, may still depend on cell context and the contempo-
raneous recruitment of activating or inhibiting factors in the same
microdomains. How GSLs located in the outer leaﬂet of the plasma
membrane interact with proteins in the inner leaﬂet is still unclear,
but recent evidence suggest that the length of the fatty acid moiety
linked to the GSL may be the key element, with GSLs containing
long C24:0 fatty acids being able to interdigitate with raft-an-
chored SFKs (reviewed in [29]).
3.2. Lipid–protein interactions
A second modality of regulation of membrane receptors by
sphingolipids and gangliosides entails speciﬁc interactions of lipids
with the receptors. One of the best-characterized models is the
modulation of epidermal growth factor receptor (EGFR) activity
by the ganglioside GM3. GM3 inhibits EGFR signaling without
interfering with EGF binding or receptor dimerization. This effect
requires the sugar headgroup of GM3, which interacts with an oli-
gosaccharide chain in the extracellular domain of EGFR [30]. In this
case GM3 works as a protein-speciﬁc escort. Rather than directly
inhibiting receptor activation, GM3 might favor receptor inactiva-
tion by targeting GM3-bound EGFR to speciﬁc membrane domains
that contain a Receptor Tyrosine Phosphatase (RTPase) responsible
for receptor dephosphorylation (reviewed in [31]). Insulin receptor
(IR) is another tyrosine kinase receptor that is inhibited by the gan-
glioside GM3. Inhibition is mediated, at least in part, by the speciﬁc
interaction of GM3 with a critical lysine residue in the receptor
[32]. This interaction disrupts the binding of IR to caveolin, which
is crucial for IR signaling, and leads to insulin resistance. In line
with this observation, mice lacking GM3 have increased insulin
sensitivity [33].
Gangliosides, in particular GM1, potentiate the action of neuro-
trophins and may activate Trk receptors even in the absence of
neurotrophins [34]. Like in the case of EGFR, glycosilation of TrkA
receptor seems to play a role in the interaction with GM1 [35].
GM1 might facilitate dimerization and receptor phosphorylation
in a manner similar to ceramide accumulation. Receptor/ganglio-
side interaction could also have a role in the trafﬁcking and target-
ing of TrkA receptor to the plasma membrane [36].
While the interactions described above are mediated by glycans
and oligosaccharide chains, some proteins contain speciﬁc sphin-
golipid-binding domains (SBD) with highest afﬁnity for galactosyl-
ceramide and SM. Examples include the nicotinic acetylcholinereceptor, PDGF receptor, Thy-1, the HIV-1 surface envelope glyco-
protein gp120 and the Ab peptide. In the case of the nicotinic ace-
tylcholine receptor, the speciﬁc interaction between SBD and
sphingolipids result in conformational changes important for
receptor assembly, trafﬁcking and function [37].3.3. Gangliosides as co-receptors
A third regulatory mechanism peculiar to gangliosides involves
their function as co-receptors that bind ligands and expose them to
the main receptor in a proper, speciﬁc orientation. An example is
given by the effect of GM1 on the ﬁbroblast growth factor 2
(FGF2) receptor. GM1 has a bimodal action on this receptor: in cells
that do not synthesize heparan sulfate proteoglycans (necessary
for ligand presentation and binding), administration of GM1 acti-
vates FGFR by directly binding FGF and allowing ligand binding
to FGFR. However, in normal cells, administration of GM1 has a
general negative effect on FGFR signaling, perhaps due to the com-
petition between heparan sulfate and GM1, or to changes in mem-
brane composition that result from GM1 enrichment. A co-receptor
role for gangliosides has been proposed also in the case of seroto-
nin and possibly other neurotransmitters with amino groups
(GABA, glutamate and some peptides such as enkephalin and sub-
stance P). Binding of serotonin to GM1 stabilizes neurotransmitter
monomers and might orient them close to the membrane for opti-
mal binding to serotonin receptors (reviewed in [37]).4. Cell adhesion/recognition and myelin–axon interactions
GSLs are involved in carbohydrate–carbohydrate and carbohy-
drate–lectin interactions that are key to the formation of ‘‘glyco-
synapses” and essential to cell–cell recognition, adhesion and
signaling. As originally deﬁned by Hakomori, glycosynapses are
membrane domains that are distinct from classical lipid rafts since
they may exist independently of cholesterol. In the glycosynapses,
the glycan structure of the gangliosides and the glycosylation state
of tetraspanins are essential for the interactions that bring together
and bridge speciﬁc extracellular proteins, tetraspanins, integrins
and other adhesion proteins, and signaling molecules. For instance,
interaction of GM3 with the tetraspanin CD9 leads to the recruit-
ment of integrin a3 in the complex and to inhibition of cell mobil-
ity. Furthermore, high levels of GM3 also recruit the Src kinase csk
into the glycosynapse, resulting in phosphorylation and inhibition
of c-Src [38].
Even outside classical glycosynapses, gangliosides facilitate the
formation of supramolecular complexes where multiple signals are
integrated. The result is often a potentiated signal. For example,
two important converging signals for neurite outgrowth in many
neural cells are activation of TrkA receptor by NGF and interaction
of the extracellular matrix protein laminin-1 with integrins. TrkA
activation alone is not enough to produce rapid and robust neurite
outgrowth. On the other side, induction of neurite outgrowth by
laminin requires the presence of NGF. Cooperation between the
two pathways is achieved by binding of laminin-1 to GM1, induc-
tion of ganglioside clustering and relocation of TrkA and b1 inte-
grin to lipid rafts. Here, the subsequent recruitment of
downstream signaling molecules such as Lyn, Akt and MAPK leads
to neurite outgrowth [39]. This peculiar role of GM1 might explain
why during axonal development, the concentration of GM1 is fo-
cally increased by sialidase Neu3 at the tip of a single neurite, lead-
ing to activation of TrkA and axonal growth [40].
One aspect of ganglioside-mediated cell–cell interaction with
paramount importance in the nervous system is the organization
of myelinated nerve ﬁbers. The interaction between myelin sheet
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tion potentials, but also for axonal trophic support. Myelin sheets
can still form normally in the absence of ganglioside synthesis in
oligodendrocytes [41]. However, neuronal gangliosides, and in par-
ticular GM1, GD1a and GT1b, are essential for the maintenance of
myelinated axons in the central and peripheral nervous system.
GM1, which is enriched in paranodal structures (Fig. 3), is critical
for lipid raft partitioning and compartmentalization of the glial
neurofascin-155 (NF-155) and the axonal contactin/caspr1 (cont-
actin-associated protein 1) proteins. These are two adhesion pro-
teins that interact with each other in trans and that are essential
for the cytoarchitecture of paranodal regions (reviewed in [42]).
In GM2/GD2 synthase null mice, lack of GM1, among other com-
plex gangliosides, results in reduced expression of caspr and NF-
155 and disruption of paranodal junctions as it occurs in Caspr
and NF-155 knock-out mice [43].
In myelinated ﬁbers GM1 could potentially modulate the activ-
ity of a third adhesion molecule, transient-axonal glycoprotein 1
(TAG-1), which is highly expressed in the juxtaparanodes and is
essential for correct localization and compartmentalization of the
Kv1.1/1.2 (Shaker-like) channels (reviewed in [42]). TAG-1 and
GM1 do associate in cerebellar granule cells [44] and TAG-1 activ-
ity depends on gangliosides in the cerebellum [45]. However, the
interaction between TAG-1 and GM1 has not been investigated in
myelinated ﬁbers, yet.
Interestingly, reduced expression of NF-155 and disorganization
of paranodal structures have been observed in early lesions in the
brain of patients with multiple sclerosis (MS) prior to demyelina-
tion. These abnormalities are accompanied by decreased expres-
sion of GSLs, galactosylceramide, sufatides and GM1 in particular,
reorganization of lipid rafts and redistribution of NF-155 outside
of lipid rafts [46]. The underlying mechanisms are not clear and
the question remains whether at least some of these abnormalities
might be caused by the presence of antibodies against GM1 and
other gangliosides in the serum of MS patients, or by increased
ganglioside-speciﬁc T and B cell reactivity [47,48].Fig. 3. Role of gangliosides in myelin–axon interactions. The molecular and cytoarchitec
and to nerve conduction. GM1 is enriched in lipid rafts at the paranodes, where it med
Interaction of MAG with GD1a stabilizes myelin–axon interaction and might also haveMyelin stability and proper axonal function also depend on the
interaction of GD1a and GT1b, the two most abundant gangliosides
in axonal membranes, with the myelin-associated glycoprotein
(MAG), a sialic acid-binding protein belonging to the family of Sig-
lecs. GD1a and GT1b are speciﬁc MAG ligands and their absence in
the myelinated ﬁbers of GM2/GD2 synthase null mice results in
impaired phosphorylation of axonal neuroﬁlaments, aberrant neu-
roﬁlament spacing and decreased axon caliber [49]. Not surpris-
ingly, GM2/GD2 synthase null mice develop a neurodegenerative
phenotype that begins with axonal degeneration and demyelina-
tion in the central nervous system and in the sciatic nerve [50]. Re-
cently, the speciﬁc binding of MAG to GD1a and GT1b has been
shown to confer protection against axonal toxicity induced by
vincrestin and other neurotoxins, perhaps through microtubule
stabilization in the axons [51].
As axonal receptors for MAG, the gangliosides GD1a and GT1b
have been implicated in the MAG-mediated inhibition of axonal
outgrowth and regeneration following axonal injuries or disease.
However, MAG interacts with other receptors on the axolemma,
including Nogo receptor (NgR), and can inhibit axonal growth by
engagement of these receptors in a ganglioside-dependent or inde-
pendent manner, based on cell context. This topic is reviewed else-
where in this special issue.
5. Sphingolipids in intracellular membranes and organelles
In addition to their crucial roles at the plasma membrane,
sphingolipids can also modulate the structure and function of
intracellular membranes and processes that involve intracellular
organelles.
5.1. Endosomes and endocytosis
Different mechanisms of endocytosis have speciﬁc protein
requirements such that they depend on dynamin, clathrin, and/or
caveolin. The requirements for lipids are also different, i.e. generaltural structure of paranodes is key to the spatial separation of K+ and Na+ channels
iates compartmentalization of the adhesion proteins NF-155 and Contactin/Caspr1.
a neurotrophic function on axons, perhaps through microtubule stabilization.
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rin-independent endocytosis but not clathrin-dependent uptake,
and selective depletion of GSLs inhibits only caveolar endocytosis
[52]. Conversely, acute treatment with exogenous natural or syn-
thetic GSLs stimulates caveolar endocytosis without affecting other
endocytic mechanism [53]. The mechanism(s) by which GSLs en-
hance caveolar endocytosis are not well understood, but Pagano’s
group has proposed two models [53]. The ﬁrst model suggests that
exogenously added GSLs may interact as membrane environment
modiﬁers or as ligands for speciﬁc plasma membrane proteins,
which, in turn, would initiate a cascade of signaling events result-
ing in activation of caveolar endocytosis. The second model pre-
dicts that addition of GSLs at the outer leaﬂet of the plasma
membrane would change the lipid distribution and organization
at both leaﬂets of the plasma membrane, which in turn could in-
duce a redistribution of lipid-modiﬁed signaling proteins on the in-
ner leaﬂet of the plasma membrane. These changes would cause
the activation of kinases at the plasma membrane and initiate
caveolar endocytosis.
As for many ceramide functions, the role of ceramide in the reg-
ulation of endocytosis is cell-type speciﬁc. The intrinsic ability of
ceramide to promote the lamellar to non-lamellar phase transition
promotes vesicle budding, membrane fusion, and ATP-indepen-
dent endocytosis [6,7]. Indeed, it has been suggested that cells
may use SMase activation as a mechanism to regulate the local li-
pid composition and to promote endocytosis [54]. In line with this
hypothesis, neurons isolated from mice lacking acidic sphingomy-
elinase (aSMase) have increased content of plasma membrane SM
in lipid rafts and show aberrant localization of GPI-anchored pro-
teins and GM1 to dendrites due to defective membrane internali-
zation in these structures [55].
An increase of membrane fusion/ﬁssion events due to ceramide
elevation at the plasma membrane could explain some subcellular
features present in the endosomal/lysosomal system during nor-
mal aging or in certain neurological disorders such as Alzheimer’s
disease (see Section 6). In contrast to the notion that ceramide en-
hances endocytosis, we found that ceramide inhibits uptake of NGF
[56]. The inhibitory effect of ceramide could be explained by a
miss-localization of NGF receptors at the plasma membrane. In-
deed, NGF-activated TrkA but not ceramide-activated TrkA moves
out of rafts to allow its internalization through clathrin-mediated
endocytosis3 due to changes of membrane microdomains that result
from ceramide accumulation.
5.2. Mitochondria and apoptosis
The nervous system has high-energy demands, which at the
neuronal cellular level become even more pronounced due to the
extremely polarized nature of neurons and the speciﬁc needs in
precise cellular compartments such as synapses. Impairment of
mitochondria function has dramatic effects on neural tissue, and
mitochondria are indeed greatly affected in many neurodegenera-
tive disorders. In addition, mitochondrial membranes act as ‘sen-
sors’ of cellular stress and respond with changes that culminate
in apoptosis. Mitochondria are also the main targets and mediators
of the pro-apoptotic role of ceramide and ganglioside GD3 in cer-
tain conditions.
While gangliosides are not normally detectable in brain mito-
chondria, a pool of mitochondrial ceramide is physiologically pres-
ent, and more abundant in synaptosomal than in non-
synaptosomal mitochondria [57]. The pool of mitochondrial cera-
mide might have multiple origins: synthesis in situ from sphingo-
sine, cleavage of mitochondrial SM, or direct exchange from ER or3 Posse de Chaves et al., unpublished observations.mitochondria associated membranes (MAMs) (Fig. 2) [58,59].
Importantly, SM present at the mitochondrion, and not at the outer
leaﬂet of the plasma membrane, seems to provide the pool of cer-
amide involved in apoptosis [58]. Ceramide inﬂuences several as-
pects of mitochondria function. It increases mitochondrial and
cytosolic Ca++ concentrations, increases the formation of reactive
oxygen species (ROS), causes ATP depletion, induces a collapse of
mitochondrial membrane potential (DWm), and induces the re-
lease of mitochondrial proteins to the cytosol [60,61]. Some of
the mechanisms by which ceramide alters mitochondrial activity
directly involve mitochondrial membranes, such as the formation
of pores that serve as channels for large proteins. Other mitochon-
dria-related processes affected by ceramide are due to the second
messenger role of ceramide, in particular inhibition of PI3K/Akt
pathway, activation of protein phosphatase 2A (PP2A) and activa-
tion of JNK [16,58,61]. Once again, which mechanism prevails in
the mitochondrial effects of ceramide is dependent on the cell type.
GD3 ganglioside is an apoptotic mediator in numerous cell
types including neurons and glial cells. GD3 is actively synthesized
and accumulates early and transiently during apoptosis. GD3 tar-
gets mainly mitochondria causing signiﬁcant mitochondrial func-
tion changes, similar to those induced by ceramide. GD3
increases production of ROS, dissipates the mitochondrial mem-
brane potential (DWm), and induces release of apoptogenic factors
such as cytochrome c, ATP, AIF, and caspases. In addition, GD3 pro-
duced upon exposure to Ab seems to be responsible for re-activa-
tion of the cell cycle in neurons [62], a condition that precedes
neural cell death. GD3 accumulation requires ceramide produced
by the action of acidic SMase, which in turns promotes the synthe-
sis and relocalization of GD3 to mitochondria [63]. At the mito-
chondria, GD3 would induce changes in membrane viscosity and
curvature, which could result in mitochondrial ﬁssion. It has been
hypothesized that the small fragments of mitochondria could act
as ‘‘cargo boats” transporting GD3 and other pro-apoptotic mole-
cules into the nucleus [64]. A recent report suggests the possible
consequences of GD3 synthase regulation in human disease by
demonstrating that elimination of GD3 synthase improves mem-
ory and reduces Ab plaque load in APP/PSEN1 mouse model of Alz-
heimer’s disease, and that in primary neurons and astrocytes
lacking GD3 synthase Ab-induced cell death is inhibited [65].
5.3. Autophagy
Autophagy represents a very important cellular process that in-
volves extensive intracellular membrane rearrangement in which
membrane dynamics play a pivotal role. Although originally seen
as a cellular resource activated under conditions of nutrient starva-
tion, autophagy also provides an essential mechanism for the clear-
ance of abnormal and misfolded proteins. There is now strong
evidence that autophagy may represent a key neuroprotective
mechanism in many neurodegenerative conditions, including AD,
PD and Huntington’s disease. Ceramide and gangliosides regulate
autophagy in a positive manner. The mechanisms involved in the
induction of autophagy by ceramide and gangliosides include reg-
ulation of protein expression, i.e. upregulation of the autophagy
gene beclin 1 [66,67] or downregulation of nutrient transporter
proteins [68], and inhibition of signaling molecules such as protein
kinase B [67]. None of these mechanisms seems to be linked di-
rectly to ceramide effects on membrane dynamics. However,
mechanisms involving ceramide induction of membrane curvature
have also been proposed [69].
Autophagy is enhanced in the brain of mice models of
GM1-gangliosidosis [66], while pharmacological reduction of gan-
gliosides levels in a cellular model of synucleinopathy causes
autophagy inhibition, due to impaired fusion between autophago-
somes and lysosomes, downregulation of Beclin-1 and ATG5, and
1754 E. Posse de Chaves, S. Sipione / FEBS Letters 584 (2010) 1748–1759upregulation of the negative regulator of autophagy mammalian
target of rapamycin (mTOR) [70]. The implications of autophagy
induction for cell fate are complex. Autophagy is indeed a Janus-
faced process which has protective roles in aging, neurodegenera-
tive diseases and infectious diseases, but may also represent a true
mode of cell death under speciﬁc circumstances [71].
5.4. Endoplasmic reticulum-nuclear membranes and Ca2+ homeostasis
The transduction of extracellular stimuli to intracellular re-
sponses by mechanisms that involve Ca2+ signaling is of vital
importance in a wide range of cellular processes. Given the func-
tion of sphingolipids in cell signaling it is not surprising that they
also contribute to regulation of cellular Ca2+ homeostasis. In most
cases their role is indirect, through modulation of signaling path-
ways that lead to elevation of intracellular [Ca2+]i in a cell-speciﬁc
manner. However, gangliosides may also have a direct effect, by
interacting with and modulating the properties of Ca2+ channels
(reviewed in [72]). In this regard, work by R. Leeden and collabora-
tors have demonstrated that GM1 (but not other gangliosides)
binds to the sodium–calcium exchanger (NCX) in the nuclear
membrane, and regulates calcium transfer from nucleoplasm to
endoplasmic reticulum [73]. This function of GM1 is important to
maintain calcium homeostasis, as demonstrated by the fact that
lack of GM1 and impaired regulation of NCX activity result in
increased susceptibility of GM2/GD2 synthase null mice to
kainate-induced seizures, excitotoxicity and apoptosis [72]. The re-
cent discovery that the sialidase Neu3 is also present in the inner
nuclear membrane, along with gangliosides GM1 and GD1a, sug-
gests that this enzyme may play a regulatory function by raising
the local concentration of GM1 and stimulating NCX activity [74].
Gangliosides might also modulate the activity of plasma mem-
brane and endoplasmic reticulum Ca2+-ATPase. Both GM3 and
GM1 have been shown to affect protein conformation and activity
of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) in
rabbit skeletal muscle, although in opposite directions, with GM3
playing a stimulatory and GM1 an inhibitory effect [75]. The signif-
icance of these ﬁndings in the context of normal cell physiology is
not clear, since these studies were performed by adding exogenous
gangliosides to membrane preparations, thus increasing ganglio-
side membrane content well beyond physiological concentrations.
However, they may help explaining why in lysosomal storage dis-
orders such as Sandhoff disease, in which cells fail to degrade GM2,
accumulation of gangliosides in the ER causes altered SERCA pump
function and impaired calcium homeostasis [76].
GM1 is also involved in modulating the activity of voltage-inde-
pendent Ca2+ channel transient receptor potential cation channel
subfamily C member 5 (TRPC5) at the plasma membrane, although
with an indirect mechanism. Experimental cross-linking of GM1 in
neuroblastoma cells results in co-clustering of a5b1 integrin in a
complex with GM1, activation of PLCc and PI3K, and calcium inﬂux
through the TRPC5 channels [77].
The effect of ceramide on the cytoplasmic Ca2+ concentration
([Ca2+]i) varies depending on the cell type and it is usually indirect.4 Sipione et al., submitted.6. Lessons from diseases and models of sphingolipid depletion
In spite of the overwhelming evidence of the role of sphingoli-
pids in membrane dynamics and cell signaling, there are surpris-
ingly few recognized pathologies due to the impairment of
sphingolipid biosynthesis. No inherited deﬁciency of ceramide syn-
thase has been reported so far. GM2/GD2 synthase deﬁciency
(leading to lack of complex gangliosides and accumulation of the
precursor GM3) has been described in a single patient with im-
paired motor development, seizures and death in infancy [78].Loss-of-function mutation in the gene encoding GM3 synthase
causes another extremely rare autosomal recessive disorder, the
infantile-onset symptomatic epilepsy syndrome, which is charac-
terized by progressive brain atrophy, epilepsy, chorea [79]. The
corresponding murine knock-out models lacking GM2/GD2 syn-
thase (lack of complex gangliosides of the 0-, a- and b-series) or
GM3 synthase (lack of a- and b-series gangliosides), display a dif-
ferent phenotype, with motor and behavioral symptoms starting
late in life in GM2/GD2 synthase null mice, and only complete
hearing loss in GM3 synthase knock-out mice [80,81]. Lack of mo-
tor symptoms and neurodegeneration in these latter mice might be
explained by compensatory up-regulation of the 0-series pathway
[82]. Such a compensatory mechanism, however, is not present in
humans with the same genetic defect [83]. These considerations
should invite to caution when extrapolating data in animal models
to human pathologies. An extensive review on models of impaired
sphingolipid synthesis and associated pathology has been pub-
lished recently [80]. In the next section of this review we will dis-
cuss the involvement of SM, ceramide and gangliosides in aging
and neurodegenerative disorders.
7. Sphingolipids in brain aging and neurodegeneration
The lipid proﬁle of the brain changes during aging and in some
neurodegenerative diseases. Most changes occur in speciﬁc brain
areas or even at distinct brain membrane microdomains. The
mechanisms responsible for lipid changes, as well as the implica-
tions of the altered lipid proﬁle depend mostly on the disease,
although some general mechanisms might exist. Aberrant conver-
sion of SM to ceramide as well as pronounced changes in ganglio-
side patterns have been involved in the pathogenesis of
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease4 (HD) and Human Immunodeﬁciency Virus (HIV) 1-related
dementia, among others [16]. Lipid-storage diseases characterized
by impaired degradation and accumulation of sphingolipids have
been reviewed elsewhere.
7.1. Aging
Some pivotal mechanisms in aging in all organs are enhanced
oxidative stress, mitochondria dysfunction and calcium dysregula-
tion. In addition, in the CNS there are dramatic changes in the
endosomal/lysosomal system characterized by increased expres-
sion of lysosomal proteases and reduction of lysosomal membrane
stability [12]. As presented above most processes involved in aging
are affected by simple sphingolipids and gangliosides.
The role of ceramide in aging has been recently reviewed [84].
Briefy, during aging there is a progressive increase in brain cera-
mide in the mouse cerebral cortex and hippocampus, and en-
hanced levels and activity of SMase mainly in striatum and
hippocampus of animal models of senescence. The evidence indi-
cates that SMase activation is secondary to activation of the insu-
lin/insulin-like growth factor 1 receptors (IR/IGF1-R), which
would cause a switch in expression levels of neurotrophin recep-
tors from TrkA to p75NTR [85]. p75NTR is responsible for activa-
tion of neutral sphingomyelinase (nSMase) and ceramide
formation. Increase in SMase activity and in ceramide levels may
contribute to the vulnerability of the striatum and hippocampus
to stress and inﬂammatory insults that lead to synaptic dysfunc-
tion and neurodegeneration [86]. In particular, ceramide enrich-
ment would make the cells more susceptible to oxidative stress,
a key process during aging and the development of neurodegener-
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ceramide.
Throughout life, the gangliosidepattern in thebrain changes con-
tinuously, with decreasing proportions of GM1 and GD1a and
increasing proportions of GD1b, GM3, and GD3. After 70 years of
age the ganglioside concentration decreases dramatically and at a
faster rate than cholesterol and phospholipids. The concentration
of GD3 in cerebral cortex increases 75% from 20 years to old age
[87]. The role of GD3 in aging might be linked to its effects on mito-
chondrial functions. IndividualC-18ganglioside species remaincon-
stant during aging, while C20-species of gangliosides increase, in
particular GM1/GD1 in the hippocampus [4]. The interpretation
has been that C20 species would decreasemembrane ﬂuidity, alter-
ingmembraneproperties andmaking the cellsmoreprone todegen-
eration. In line with studies performed on brains, lipid rafts isolated
from neurons aging in vitro have high content of sphingolipids, par-
ticularly ceramide, decreased levels of gangliosides, and show
changes in the pattern of associated proteins [88]. The opposing
direction in the changes of ceramide and gangliosides during devel-
opment and aging has served as the foundation for the development
of an interesting concept that predicts the progression from ‘‘glyco-
signaling domains” during development to ‘‘ceramide signaling
domains” during aging [88]. However, changes in lipid composition
of brain lipid rafts during aging are not uniform. Lipid rafts isolated
from mouse brain synaptosomes get enriched in GM1 [89]. This
enrichment is brain region speciﬁc, more pronounced in mice
expressinghumanapoE4 (an important risk factor forAD), and resis-
tant to the treatment with the cholesterol sequestering agent
methyl-b-cyclodextrin [89]. Duringaging, GM1accumulates in clus-
ters only in synaptosomes, and not in other brain lipid rafts, possibly
as the result of SM increase, which also takes place in synaptosomes
exclusively. These changes have been linked to the development of
Alzheimer’s disease (see below) [90].
7.2. Alzheimer’s disease
The role of ceramide and other lipids in AD has been recently re-
viewed [16,84], thus the reader is referred to this work for a de-
tailed discussion of original papers.
Ceramide increases very early in the brain of AD patients. aSM-
Ase activity is elevated in brains of AD patients when compared to
healthy, age-matched brains [91], likely due to the membrane-
associated oxidative stress characteristic of AD. However, the
molecular species of ceramide in AD brains correlate better with
sulfatide molecular species than with SM molecular species, and
brain sulfatide levels are reduced.
In AD an interesting reciprocal regulation exists between sphin-
golipids and Ab (Fig. 4A), the characteristic amyloidogenic peptide
that accumulates in the brain. Sphingolipids regulate amyloid pre-
cursor protein (APP) cleavage and Ab production by means of the
localization of the two enzymes that cleave APP in the amyloido-
genic pathway, c-secretase and b-site APP-cleaving enzyme
(BACE), to lipid rafts. SM reduction and ceramide stabilize BACE1
and promotes b cleavage of APP. Importantly, the mechanism of
BACE1 stabilization appears independent of the formation of cera-
mide platforms but seems to result from a more direct regulation
of BACE by ceramide and other lipids [92]. Lipid rafts are also
important in neuronal uptake of Ab. We have demonstrated that
Ab uses a raft-dependent endocytic pathway for internalization
into neurons and that inhibition of sphingolipid and cholesterol
synthesis signiﬁcantly reduces neuronal uptake of Ab [93]. There-
fore, sphingolipids could regulate the level of intraneuronal Ab,
which is important for brain toxicity and synaptic plasticity abnor-
malities in AD.
The reciprocal aspect of sphingolipid functions in AD is repre-
sented by the role of ceramide as second messenger of Ab cytotox-icity. Many mechanisms are responsible for ceramide
accumulation downstream of Ab [84].
The role of gangliosides in the pathology of AD has been re-
cently reviewed [94,95], then we will only mention the main
mechanisms by which gangliosides inﬂuence AD. In the brain of
AD patients the pattern of gangliosides is signiﬁcantly changed in
a region- and ganglioside-speciﬁc manner. Gangliosides are in-
volved in many important cellular processes that are linked to
AD development, thus it is difﬁcult to reach a verdict whether they
are beneﬁcial or detrimental.
Defective GSL synthesis decreases APP cleavage by a- and b-
secretase by impairing the transport of APP through the secretory
and endocytic pathway, and to the plasma membrane and endo-
somes where the secretases are located [92,96]. In agreement,
studies in vitro demonstrated that administration of exogenous
GM1 increases secretion of Ab [97], suggesting that GM1 therapy
would be detrimental for AD. Nevertheless, systemic delivery of
GM1 to transgenic mice overexpressing APP causes a substantial
decrease in the levels of soluble Ab and a reduction of amyloid bur-
den in the brain [98]. These apparent discrepancies can be recon-
ciled if one considers the different route of delivery. When GM1
is provided directly to cells it will incorporate into the plasma
membrane and will change membrane dynamics favoring the ac-
cess of secretases to APP. On the other hand GM1 delivered sys-
temically would bind to Ab triggering a ‘‘sink” effect at the
periphery without acting at the brain cellular level.
One of the most signiﬁcant aspects of the role of GM1 and other
gangliosides in AD results from their ability to bind Ab [95]
(Fig. 4A). Ab binds to membranes containing GM1, and upon bind-
ing, it undergoes a conformational transition from random coil to
an ordered structure rich in b-sheet. GM1 acts as seed for Ab ﬁbril-
lation in the brain (reviewed in [94]). The seeding process starts
with an increase in GM1 at the plasma membrane, possibly as a
consequence of abnormalities in the late endocytic pathway [99].
High-density GM1 clustering induces Ab assembly in presynaptic
neuritic terminals in the brain in an age-dependent, and partially
brain-region-speciﬁc manner [90]. This particular localization of
GM1 clusters is in line with evidence of Ab deposition at the pre-
synaptic neuritic terminals [94].
Other gangliosides also interact with Ab causing Ab accumula-
tion in the brain. The assembly of wild-type and mutant forms of
Ab is accelerated in the presence of GM1, GM3 and GD3 ganglio-
sides (reviewed in [94]. Moreover, elimination of GD3 synthase
(GD3S) in a triple transgenic model APP/PSEN1/GD3S/ improves
memory and reduces Ab plaque load [65]. These animals have de-
creased levels of GD3 but increased GM1 and GD1a, therefore it re-
mains to be determined whether the effects observed were due to
decreased GD3, increased GM1 or both.
A new role for gangliosides in AD has been recently proposed.
The sialic acid moieties of gangliosides present in neuritic plaques
in complexes with Ab would serve as ligands for the receptor Sig-
lec-11, a negative immune regulator expressed in microglia. By
activating this receptor neuritic plaques would be able to evade
the immune surveillance of microglial cells [100]. Sialylated glyco-
proteins present in neuritic plaques would play a similar role sug-
gesting that plaque accumulation in AD could be exacerbated by
glycosylation of amyloid aggregates and consequent down-regula-
tion of microglia function.
7.3. Parkinson’s disease
PD belongs to a group of conditions called synucleinopathies,
which are characterized by the presence of ﬁbrillary aggregates
of a-synuclein protein in the cytoplasm of selective populations
of neurons and glia. Hallmarks of PD are progressive degenera-
tion of dopaminergic neurons in the substantia nigra and
Fig. 4. Role of sphingolipids in AD and HIV-related dementia. (A) Localizaion of BACE1 and c-secretase to lipid rafts enhances APP cleavage and production of Ab. Ceramide
has also a direct stimulatory action of BACE. The interaction of Abwith GM1 at the plasma membrane induces Ab ﬁbrillation. Sphingolipids in lipid rafts are also crucial for Ab
internalization into neurons. Finally, Ab increases production of ceramide by a variety of mechanisms, and ceramide mediates at least some of the cytotoxic effects of Ab. (B)
In HIV-related dementia lipid rafts help viral binding to the surface of target cells and viral fusion. GSLs binding to the viral protein gp120, promotes the interaction of the
complex CD4/gp120 with the co-receptor CXCR and consequent viral fusion. Ceramide has both beneﬁcial and detrimental roles. Increased production of ceramide blocks
viral fusion. However, ceramide may also mediate viral toxicity.
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lieved that oligomers and protoﬁbrils of a-synuclein may play a
causative role in neurotoxicity. Hence, inhibiting the aggregation
of a-synuclein may constitute a rational therapeutic approach.
GM1 interacts with a-synuclein and inhibits its aggregation
in vitro [101], raising the possibility that endogenous gangliosides
might prevent a-synuclein aggregation in vivo. Gangliosides might
also impair signaling mechanisms activated by a-synuclein by
affecting the composition of caveolar membranes where a-synuc-
lein is located. There is also extensive evidence of the beneﬁcial ef-
fects of GM1 supplementation in animal models of PD [102]. Based
on this evidence, it is conceivable that the elevated levels of anti-
GM1 antibodies found in some PD patients would block normal
GM1 function and could play a role in disease pathogenesis [103].
With respect to simple sphingolipids, in PD the conversion of
SM to ceramide is affected (reviewed in [61]). There is a dramatic
increase in SMase levels in the dopaminergic system and a differ-
ential regulation of aSMase versus nSMase. The oxidative stress
that results from cathecolamines metabolism in dopaminergic
neurons activates nSMase, causing an elevation of ceramide levels.
Ceramide derived from SM might be responsible for the apoptosis
observed in the substantia nigra, since a reduction of ceramide is
protective against the speciﬁc dopaminergic toxin.
7.4. HIV-associated dementia
From the patients suffering from acquired immunodeﬁciency
syndrome (AIDS), 20-30% present severe neurological disabilities
identiﬁed as Human immunodeﬁciency virus type 1 (HIV-1)-asso-ciated dementia (HAD). HAD is linked to neuronal death but the ex-
act mechanisms of HIV-induced apoptosis have not been
completely elucidated. Interaction of the HIV-1 envelope glycopro-
tein gp120 with CD4 and the co-receptors CXC chemokine receptor
4 and 5 (CXCR4 and CCR5) present on the host cell surface, medi-
ates viral fusion [16]. Lipid rafts play a major role in HIV1-fusion
and consequently, their disruption by cholesterol depletion causes
inhibition of HIV infection [104].
Various GSLs binds to gp120 through its SBD (see Section 2),
galactoceramide with high afﬁnity and GM3 and Gb3 with low
afﬁnity [104]. The interaction with GSLs helps stabilizing the virus
at the cell surface, promoting the lateral motion of the complex
CD4-gp120 to reach the co-receptor and aiding in the conforma-
tional changes of gp120 required for fusion (Fig. 4B). Therefore,
the role of GSLs in HAD is mainly detrimental.
Ceramide may have both positive and negative effects on HAD.
On one side, increasing ceramide biosynthesis makes cells resistant
to HIV infection due to inhibition of membrane fusion, to the ex-
tent that the ceramide biosynthetic pathway has been proposed
as a possible novel target for HIV treatment (reviewed in [16])
(Fig. 4B). On the other hand overproduction of ceramide may be in-
volved in neuronal death in HAD patients [105]. There is evidence
that an early dysfunction of sphingolipid metabolism leads to accu-
mulation of ceramide in cerebrospinal ﬂuid (CSF) of HIV patients
with active dementia due to increased SMase activity, while higher
levels of SM are present in CSF of HIV patients with inactive
dementia [106]. Studies in cultured neurons have shown that
gp120, induces the activation of SMase and generation of ceramide
by coupling to the CXCR4 and the induction of NADPH
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evidence, Jana and col. suggested that speciﬁc targeted inhibition
of nSMase may be an important therapeutic approach to prevent
neuronal damage in HAD [84].
7.5. Huntington’s disease
Huntington’s disease (HD) is an inherited neurodegenerative
disorder determined by the expansion of a poly-glutamine (polyQ)
stretch in the protein huntingtin (Htt). Misfolded mutant Htt
(mHtt) forms intra-neuronal toxic oligomers and protein aggre-
gates, resulting in the development of a broad array of cell dysfunc-
tions, including transcriptional dysregulation, mitochondrial
metabolism aberrations, and impairing cell signaling, axonal trans-
port and synaptic activity. In addition, HD cells have increased sus-
ceptibility to stress and apoptotic stimuli.
We have recently demonstrated that levels of GM1 are lower
than normal in cell and animal models of HD and in ﬁbroblasts
from HD patients.5 Transcriptional dysregulation of the ganglioside
biosynthetic genes was also recently conﬁrmed in another model of
HD [107]). Interestingly, our data suggest that levels of GM1 at the
plasma membrane of HD cells correlate with cell susceptibility to
apoptosis. Restoring normal ganglioside content in HD striatal cells
by GM1 administration results in protection from cell death. Vice
versa, decreasing GM1 in normal cells reproduces the susceptibility
to apoptosis that is typical of HD. Therefore, GM1 at the plasma
membrane of HD cells may play a role in the cell response to stress,
perhaps by modulating the activation of pro-survival and/or pro-
apoptotic pathways. Indeed, we have found that GM1 restores nor-
mal levels of active AKT, a pro-survival kinase the activation of
which has been shown to be suboptimal in HD. In addition, GM1
administration leads to phosphorylation of mHtt, an event that is al-
ways associated to reduced mHtt toxicity and improved HD cell sur-
vival. Therefore, a ganglioside restorative therapy might be highly
beneﬁcial to HD patients.
8. Gangliosides and neuroprotection
The pharmacological use of gangliosides for neuroprotection
has been tested since the late 80s. A plethora of studies in animal
(including primates) and cell models has shown that administra-
tion of the ganglioside GM1 protects neurons from a variety of in-
sults, ranging from mechanical injury to exposure to neurotoxins,
growth factor deprivation and excitotoxicity (reviewed in [34]).
How GM1-mediated neuroprotection is achieved in this vast diver-
sity of experimental models is not completely understood, but
most likely the mechanisms involved are multiple and different
depending on the model used. The neuroprotective role of GM1
in models of excitotoxicity may stem from the ability of this gan-
glioside to regulate nuclear Ca2+ homeostasis [72]. In addition,
GM1 might exert a neurotrophic function similar to neurotrophins,
thanks to its ability to activate Trk receptors and downstream pro-
tective kinases [108]. Furthermore, GM1 administration has been
shown to lead to increased transcription and release of NGF and
neurotrophin 3 (NT-3), while a semisynthetic analogue of GM1,
Liga20, induces release of BDNF (reviewed in [34]). Any of these
general protective mechanisms would be beneﬁcial in most neuro-
degenerative conditions. In the case of pathologies such as Alzhei-
mer, Parkinson and Huntington’s disease, in which the presence of
toxic misfolded proteins or peptides is a common denominator of
neural dysfunction, GM1 might activate additional protective
mechanisms, such as stimulation of autophagy [70] or induction5 Maglione et al., submitted.of ﬁbrillogenesis and aggregation of toxic misfolded proteins, as
described in Section 7.
In spite of the strong evidence of the neuroprotective effect of
GM1 in animals and in in vitro models, early clinical trials in pa-
tients with stroke [109], Parkinson’s disease [110] and spinal cord
injury [111] have been disappointing or inconclusive at best. It is
now evident, that at least some of these studies had ﬂaws in the
design or used GM1 doses that were 10–50 times lower than the
therapeutic dose established for rats [109]. These considerations,
together with the low permeability of the blood-brain barrier to
GM1, might explain the overall lack of GM1 efﬁcacy in clinical
studies. GM1 analogues like LIGA-20, which is more prone to cross
the blood-brain barrier, might have improved bioavailability and
beneﬁts [34], however, at least in certain cases its mechanism of
action has been shown to be different from GM1 [112]. Continuous
intracerebral administration of the ganglioside (for up to 1 year)
was tested in a small number of early onset Alzheimer patients.
Although the authors of that study reported a small improvement
of cognitive functions, as well as improvedmood and motor perfor-
mance in the patients [113], a real beneﬁt of the therapy could not
be proved due to the small number of patients enrolled and the ab-
sence of appropriate controls. Nevertheless all these studies have
demonstrated that GM1 administration in patients is safe and that
adverse effects, such as the development of anti-GM1 antibodies
leading to peripheral neuropathy, are rare [109]. Based on these
considerations and on our data on the neuroprotective role of
GM1 in HD, we believe that GM1 may represent a viable therapeu-
tic approach especially in HD patients.
9. Concluding remarks
The impressive number of processes regulated by simple sphin-
golipids and gangliosides has proven that, as anticipated by their
enrichment in the nervous system, these lipids have a pivotal role
in neuronal function. As our understanding of the molecular events
involving sphingolipids and gangliosides increases it becomes clear
that general mechanisms at the membranes where these lipids re-
side do take place, but ultimately at least some speciﬁcitymust exist
to secure the appropriate cell response. Thus, the challenge to iden-
tify how the speciﬁcity is achieved in a particular context continues.
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